Voyager Therapeutics Inc

VYGR

Add to Watchlist

3.765USD

-0.475-11.20%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Voyager Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

60 / 382

Overall Ranking

171 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Voyager Therapeutics Inc Highlights

StrengthsRisks

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 40.37M.

Fairly Valued

The company’s latest PE is -1.90, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.49M shares, increasing 11.34% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 104.15K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.16.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

15.375

Target Price

+262.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Voyager Therapeutics Inc is 7.46, ranking 84 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.59M, representing a year-over-year decrease of 59.94%, while its net profit experienced a year-over-year decrease of 9.94%.

Score

Industry at a Glance

Previous score

7.46

Change

0



Financials

8.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.01

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.57

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Voyager Therapeutics Inc is 7.59, ranking 94 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.90, which is -1819.20% below the recent high of 32.73 and -3059.07% above the recent low of -60.14.

Score

Industry at a Glance

Previous score

7.59

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Voyager Therapeutics Inc is 9.00, ranking 17 out of 382 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 25.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.09

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Voyager Therapeutics Inc is 6.38, ranking 249 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.27 and the support level at 3.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.51

Change

-2.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Voyager Therapeutics Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.36%, representing a quarter-over-quarter increase of 18.22%. The largest institutional shareholder is James Simons, holding a total of 578.02K shares, representing 0.96% of shares outstanding, with 340.47% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Neurocrine Biosciences Inc

8.58M

--

EcoR1 Capital, LLC

4.00M

+497.17%

Armistice Capital LLC

4.00M

-4.76%

BlackRock Institutional Trust Company, N.A.

3.92M

+3.56%

Millennium Management LLC

3.41M

+81.20%

Vestal Point Capital, LP

1.48M

--

BlackRock Financial Management, Inc.

1.33M

-7.21%

Opaleye Management Inc.

1.20M

--

Geode Capital Management, L.L.C.

1.14M

-1.17%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Voyager Therapeutics Inc is 4.18, ranking 97 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Voyager Therapeutics Inc

VYGR

7.00 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment